Get It in Writing: How to Make Medications for Opioid Use Disorder Available During Incarceration
- PMID: 38150232
- PMCID: PMC11071097
- DOI: 10.1089/jchc.23.08.0065
Get It in Writing: How to Make Medications for Opioid Use Disorder Available During Incarceration
Abstract
In a case example from the Kentucky HEALing Communities Study, extensive resources were deployed to address structural barriers and facilitate the provision of medication for opioid use disorder (OUD) in an urban county jail. However, implementation was unsuccessful, and this case example emphasizes the importance of including evidence-based medication for OUD (MOUD) treatment in the scope of work of jails' contracted medical providers. The privatization of correctional health care services allows local governments with opioid abatement funds to incorporate requirements into medical provider contracts to screen all people entering jails for OUD and to offer MOUD at intake, throughout incarceration, and upon release to everyone for whom it is clinically indicated. We provide sample contractual language that can be added to requests for medical provider proposals to help drive the private correctional health care market toward integrating MOUD treatment into their standard of care. This approach also could expedite efforts to scale up broad MOUD access across U.S. jails through sharing of workflows and best practices among the small group of national correctional health care companies contracted with jails in states with broad mandates, such as Massachusetts. Clinical Trial Registration: NCT04111939.
Keywords: MOUD; contracted correctional health care; county jails; implementation science; medications for opioid use disorder.
Conflict of interest statement
M.R.L.: In the last 3 years, she served as a scientific consultant to Titan, Berkshire Biomedical, and Journey Colab for treatments in development for substance use disorders that are not related to the topic in this article. She serves as a research consultant to Braeburn about ER buprenorphine (Brixadi®) for OUD treatment. S.L.W.: In the last 3 years, she served as a scientific consultant to AstraZeneca, Cerevel Therapeutics, and Titan Pharmaceuticals on the development of novel treatments for OUD that are not related to the topic in this article. She serves as a research consultant to Braeburn about ER buprenorphine (Brixadi) for OUD treatment.
References
-
- Chatterjee, A., Weitz, M., Savinkina, A., Macmadu, A., Madushani, R. W. M. A., Potee, R. A., Ryan, D., Murphy, S. M., Walley, A. Y., & Linas, B. P. (2023). Estimated costs and outcomes associated with use and nonuse of medications for opioid use disorder during incarceration and at release in Massachusetts. JAMA Network Open, 6(4), e237036. 10.1001/jamanetworkopen.2023.7036 - DOI - PMC - PubMed
-
- Milov-Cordoba, M. (2020, November 17). Mismanaged care: Exploring the costs and benefits of private vs. public healthcare in correctional facilities. NYU Law Review. https://www.nyulawreview.org/issues/volume-95-number-5/mismanaged-care-e...
-
- Pivovarova, E., Evans, E. A., Stopka, T. J., Santelices, C., Ferguson, W. J., & Friedmann, P. D. (2022). Legislatively mandated implementation of medications for opioid use disorders in jails: A qualitative study of clinical, correctional, and jail administrator perspectives. Drug and Alcohol Dependence, 234, 109394. 10.1016/j.drugalcdep.2022.109394. https://www.sciencedirect.com/science/article/pii/S0376871622001314?via%... Last accessed December 14, 2023. - DOI - PMC - PubMed
MeSH terms
Substances
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Medical